More From Our Sponsor:
Craneware

SPONSORED CONTENT

In the complex landscape of healthcare, compliance with the Health Resources and Services Administration’s (HRSA) 340B program is paramount for covered entities. As organizations strive to optimize their participation in the program, one critical aspect is preparing for HRSA audits. To shed light on this crucial process, we turn to Kristin Andolfo, a seasoned expert in navigating HRSA audits. Kristin is a 340B ACE Senior Consulting Advisor at The Craneware Group.

With over 300 HRSA audits under its belt, along with extensive experience in handling manufacturer, state, and external audits, The Craneware Group is uniquely positioned to offer valuable insights on how covered entities can effectively prepare for HRSA audits.  See our step by step below guide below:

1. Alert and Gather All Key Players  

The first step in preparing for a HRSA audit is to ensure that all relevant stakeholders within the organization are informed and engaged. This includes representatives from pharmacy, finance, compliance, and any

SPONSORED CONTENT

With so many challenges facing health systems today — from 340B contract pharmacy restrictions to drug shortages, labor issues, and ever-rising costs — revenue integrity has become essential to financial stability.

With huge increases in drug expenditures from pre-pandemic levels, health systems must focus on maximizing efficiency, reducing medication costs, and increasing revenue. In this new reality, hospital pharmacies should think and act like a business unit, not just a cost center. Yet many hospitals unknowingly receive reimbursements that fall short of their medication costs, leading to financial strain and plenty of stress and anxiety for hospital and pharmacy administrators.

In healthcare, revenue integrity refers to the comprehensive approach organizations take to ensure accurate billing, appropriate reimbursement, and proper and efficient utilization of resources. For some hospitals, it represents a new way of doing business. If there are gaps and silos in their processes, it’s hard to achieve optimal medication revenue cycle performance.